Skip to content

Safety and Effectiveness of Taking Choline Supplements During Pregnancy for Improving Infant Brain Development

Double-blind Trial of Phosphatidylcholine During Pregnancy and Infant Serum Choline Levels

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00332124
Enrollment
351
Registered
2006-06-01
Start date
2006-06-30
Completion date
2017-03-31
Last updated
2020-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy, Child Development

Brief summary

This study will evaluate the safety and effectiveness of taking choline supplements during pregnancy, and whether choline supplementation has an effect on infant development.

Detailed description

Choline is an essential nutrient that can be found in foods, such as egg yolks, liver, and other meats. It is important for the composition and repair of normal cellular membranes, normal brain function, and normal cardiovascular function. Research has suggested that the presence of adequate amounts of choline during pregnancy and breastfeeding can help ensure healthy fetal brain development. Additionally, adequate prenatal choline levels may have long-lasting positive effects on cognitive function, including memory. However, sufficient research has not been done on the effects of choline on pregnant women and their unborn babies. This study will evaluate the safety and effectiveness of taking choline supplements during pregnancy, and whether taking choline during pregnancy will have an effect on infant development. Participants in this double-blind study will be randomly assigned to receive either placebo or 900 mg of choline daily throughout pregnancy, until delivery. Babies will then begin receiving either placebo or choline daily from the time of birth until they are 3 months old. Participants will attend a baseline study visit that will include eligibility assessment, urine collection, measurement of vital signs, dispensing of study medication, and an ultrasound. Subsequent study visits will occur every 4 weeks throughout pregnancy and 6 months postpartum. Vital signs will be taken, urine samples will be collected, and study medication will be given at each visit. Two blood samples will be taken between Weeks 32 and 36 of gestation. Heel sticks will be performed on babies when they are 4 and 12 weeks old. Follow-up visits will be held every 6 months until the baby is 18 months old.

Interventions

900 mg every day until birth of infant

DIETARY_SUPPLEMENTPlacebo

Corn oil every day in place of choline

Sponsors

University of Colorado, Denver
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
Yes

Inclusion criteria

* Pregnant * Between 10 and 18 weeks gestational age * Healthy * Diagnosis of psychosis

Exclusion criteria

* Use of any tobacco or nicotine product * Drinks more than 1 alcoholic drink per day * Use of illicit drugs * History of trimethylaminuria * History of kidney disease * History of liver disease * History of pre-pregnancy diabetes * History of Parkinson's disease * History of fetal death, fetal/infant congenital malformation, or fetal/infant genetic abnormality * Evidence of noncompliance to study medication

Design outcomes

Primary

MeasureTime frame
Sensory Gaiting (P50)Measured at birth, 1 month and 3 months after birth

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026